Patent analysis of new target oral drugs for type 2 diabetes mellitus
- VernacularTitle:2型糖尿病新靶点口服药专利分析
- Author:
Lei WANG
1
;
Yongbin DING
2
;
Dawei YANG
1
Author Information
1. Dept. of Pharmacy，Nanjing Hospital Affiliated to Nanjing University of Traditional Chinese Medicine （The Second Hospital of Nanjing），Nanjing 210003，China
2. Dept. of General Surgery，Jurong Branch of Jiangsu People’s Hospital，Jiangsu Zhenjiang 212499，China
- Publication Type:Journal Article
- Keywords:
type 2 diabetes mellitus;
new target oral drugs;
glucokinase activator;
protein tyrosine phosphatase 1B inhibitor
- From:
China Pharmacy
2023;34(22):2695-2700
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the patents of new target oral drugs for type 2 diabetes mellitus （T2DM）， and to provide references for the research and development direction and patent layout of new domestic diabetes drugs. METHODS Based on global patent data in the HimmPat database， from multiple perspectives such as the number of patent applications and authorization， development trend， regional distribution and main applicants， statistics and analysis were performed for the patents related to 3 types of new target oral drugs for T2DM， such as glucokinase activator （GKA）， protein tyrosine phosphatase 1B inhibitor （PTP-1B-IN）， and 11β-hydroxysteroid dehydrogenase 1 inhibitor （11β-HSD1-IN）. RESULTS & CONCLUSIONS A total of 1 649 patents of GKA， 709 patents of PTP-1B-IN， 592 patents of 11β-HSD1-IN were obtained， the main applicants were well-known pharmaceutical companies， which possessed the core patents of pharmaceutical compounds. The research on GKA drugs was more mature， with a larger number of patent applications and a more comprehensive enterprise layout. Domestic enterprises， universities and research institutions had advantages in the field of PTP-1B-IN. Domestic enterprises and research institutions can leverage the advantages of traditional Chinese medicine and resources to enhance their research capabilities and improve technological competitiveness through core technology exploration， the exploration of process route， patent layout， industry- university-research cooperation and the establishment of patent pool.
